Using an intravenous EAB sensor we performed feedback control over the concentration of doxorubicin, an anthracycline chemotherapeutic, in the plasma of live rats. Using a second sensor placed in the ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

For patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis, semaglutide is associated with improved liver histologic outcomes.

we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks.

Results of part 1 of the ESSENCE phase 3 trial, published in The New England Journal of Medicine, demonstrated that a greater proportion of patients with MASH achieved resolution of ...

More than half of adults with MASH receiving semaglutide had resolution of steatohepatitis at 72 weeks. A reduction in liver fibrosis stage was observed among 36.8% of the semaglutide group.

Semaglutide increased maximum walking distance by 13% compared with placebo. Treatment with semaglutide improved maximum walking distance in patients with type 2 diabetes (T2D) and symptomatic ...